Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and ...

Administration of the novel Flt3 inhibitor, crenolanib, in conjunction with intensive chemotherapy, results in high response rates with acceptable toxicity supporting its current evaluation in a ...

Acute leukemia is thought to arise from leukemic stem cells, the properties of which have only recently begun to be characterized. 8,9 FLT3 was originally identified by its expression in hematopoietic ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

Measurement of minimal residual disease (MRD) following treatment of blood cancers is recognized as an important tool for disease management, and MRD negativity is increasingly a benchmark in clinical ...

Hypocellular acute myeloid leukemia: Better or worse prognosis. Background: FLT3 (fms-related tyrosine kinase 3) with internal tandem duplication (ITD) is a known adverse prognostic factor in normal ...

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase ...

Novartis’ FLT3 inhibitor Rydapt was a much-welcomed addition to the armamentarium against acute myeloid leukemia when it was approved last year. Now, Daiichi Sankyo has data that could allow it to ...

Hangzhou Polymed Biopharmaceuticals Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer.